Liz McKee Anderson
Liz McKee Anderson is a seasoned executive with three decades of experience guiding sales and marketing strategy for some of the world’s major life sciences companies. Recently retired as Worldwide Vice President of Infectious Disease and Vaccines for the Janssen Pharmaceutical Companies of J&J, Liz championed strategic and business cases for over 25 internal and external assets to build Janssen’s IDV business and propel its growth, including the acquisition of Crucel N.V., a key platform for J&J’s vaccine portfolio development.
Prior to assuming that post, Liz served as Janssen’s WWVP, Immunology and Respiratory, Global Strategic Marketing, where she was responsible for commercial pipeline development and lifecycle management of a sizeable portfolio of small and large molecules, including Stelara and Simponi.
Before joining J&J, Liz held the position of Vice President and General Manager of Wyeth Vaccines, where she managed a 400-person commercial sales and marketing team. While at Wyeth, she oversaw the launch of Prevnar, a first-in-class vaccine that achieved $1 billion in sales in the first 18 months, qualifying it as the most successful launch in Wyeth’s 75-year history. She has also served as Vice President and General Manager for the US biopharmaceutical business of Rhone Poulenc Rorer, and before that, the VP of Business Operations for its Armour subsidiary. Her experience extends beyond sales and marketing to medical and regulatory affairs, and includes market-leading products that target both hospital and outpatient markets.
Liz combines an aptitude for strategic thinking with a track record of enterprise management and implementation that make her one of the most respected leaders in the pharmaceutical industry, and one of the sector’s leading women executives. Her reputation for creating and deploying growth strategies has elevated her to cross-functional leadership positions throughout her career, including various oversight committees as J&J. Currently, Liz serves as a member of the board of directors of Revolution Medicines.
Liz received her undergraduate degree from Rutgers College of Engineering and an MBA in Finance from the Sellinger School of Business and Management, Loyola University in Maryland.